Neumora Therapeutics, Inc. Common Stock
NMRA
Rank in Stocks
#20081
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$0.4859
Last synced: 2026-11-09
Market Cap
$91.30M
Change (1 day)
-3.46%
Change (1 year)
-82.33%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Neumora Therapeutics, Inc. Common Stock (NMRA)
Category
Healthcare
EPS for Neumora Therapeutics, Inc. Common Stock (NMRA)
EPS as of June 2026 TTM: $-1.23
According to Neumora Therapeutics, Inc. Common Stock's latest financial reports, its current EPS (TTM) is $-1.23. At the end of 2025 the company had an EPS of $-1.45, an increase over its 2024 EPS of $-1.53.
EPS history for Neumora Therapeutics, Inc. Common Stock from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.23 | -15.17% |
| 2025 | $-1.45 | -5.23% |
| 2024 | $-1.53 | 2.68% |
| 2023 | $-1.49 | 73.26% |
| 2022 | $-0.86 | -44.87% |
| 2021 | $-1.56 | 140.00% |
| 2020 | $-0.65 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,373.17% |
US
|
|
| $-7.07 | 474.80% |
US
|
|
| $-5.29 | 330.08% |
AU
|
|
| $12.88 | -1,147.16% |
BE
|
|
| $21.56 | -1,852.85% |
NL
|
Questions about Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS)
What is Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS)?
Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS) over the last twelve months is $-1.23, as of Jun 2026.
What was Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS) in 2025?
In 2025, Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS) was $-1.45, compared with $-1.53 in 2024.
How has Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS) was highest in 2020 ($-0.65) and lowest in 2021 ($-1.56).
How does Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS) compare with similar companies?
Neumora Therapeutics, Inc. Common Stock's earnings per share (EPS) ($-1.23) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.